<DOC DOCNO="nw/wsj/04/wsj_0460@0460@wsj@nw@en@on">
<ENAMEX TYPE="ORG">Cetus Corp.</ENAMEX> said the government of <ENAMEX TYPE="GPE">Spain</ENAMEX> approved the marketing of its Proleukin interleukin - 2 drug to treat kidney cancer .
The biotechnology concern said <ENAMEX TYPE="DATE">Spanish</ENAMEX> authorities must still clear the price for the treatment , but that it expects to receive such approval by <ENAMEX TYPE="DATE">year end</ENAMEX> .
<ENAMEX TYPE="CARDINAL">Four</ENAMEX> other countries in <ENAMEX TYPE="LOC">Europe</ENAMEX> have approved Proleukin in <ENAMEX TYPE="DATE">recent months</ENAMEX> .
<ENAMEX TYPE="ORG">Cetus</ENAMEX> is currently trying to obtain federal regulatory clearance for <ENAMEX TYPE="GPE">U.S.</ENAMEX> distribution .
</DOC>
